

# Personalized Stem Cells Secures \$2.5 Million in Series A Financing Round

San Diego based stem cell company, Personalized Stem Cells, Inc. secures \$2.5 million in Series A financing round.



POWAY, CALIFORNIA, UNITED STATES, July 15, 2020 /EINPresswire.com/ -- San

Diego based regenerative medicine company, [Personalized Stem Cells, Inc.](#) (PSC), has secured \$2.5 million in a Series A round of financing led by seed investors and key opinion leaders in the field. The funds will enable PSC to complete the current FDA approved osteoarthritis clinical trial and to initiate clinical trials for Traumatic Brain Injury and Back Pain. The funds will also enable conduct of a [clinical trial for treatment of COVID-19 patients](#) with stem cells, expected to enroll starting by early August.

“

PSC is a vital leader in advancing stem cell therapy and providing treatment options for orthopedics as well as medical conditions with limited treatment options.”

*Dr. Peter Hanson, Board-Certified Orthopedic Surgeon*

CEO of PSC, Dr. Bob Harman, stated, “We are pleased to welcome our new investors into the PSC family. Securing funding during these uncertain times is evidence of the strong belief in the power of regenerative medicine and in the PSC business model to deliver this critical therapy to patients.”

Dr. Peter Hanson, Board-Certified Orthopedic Surgeon

with 28 years of clinical experience and more than five years’ experience with Regenerative Medicine, stated, “I am honored to be part of the PSC investigator group. Based on my experience with stem cell therapy, I did not hesitate to participate. PSC is a vital leader in advancing stem cell therapy and providing treatment options for orthopedics as well as medical conditions with limited treatment options.”

PSC received FDA approval and initiated a [clinical trial for treatment of knee osteoarthritis](#) in their first year of operation. The Series A funding will allow for expanded and accelerated clinical trials. PSC anticipates additional milestone events including FDA approval of its landmark COVID-19 clinical study and completion of enrollment in its knee osteoarthritis phase 1/2a clinical study. After achieving these milestones, PSC anticipates an additional stock offering at a higher valuation.

About Personalized Stem Cells, Inc.

Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians a GMP compliant stem cell product for use in approved clinical trials. PSC has licensed a portfolio of patents and applications in the field of regenerative medicine which includes patents covering treatment of lung diseases including COVID-19.

Michael Dale, President/COO

Personalized Stem Cells, Inc

+1 833-772-3557

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/521622908>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.